Home ::> Staff Listings ::> Staff Listing by Name ::> T ::> Helen Tremlett
STAFF LISTING
Dr. Helen Tremlett, PH.D
Addresses:
Division of Neurology, Dept of Medicine (UBC)
S178 Koerner Pavilion
2211 Wesbrook Mall
Vancouver BC Canada V6T 2B5Tel: (604) 822-0759
Research Interests:
Pharmacoepidemiology, epidemiology, multiple sclerosis
Side-effects of the immunomodulatory drugs for multiple sclerosis
Natural history of multiple sclerosis: disease progression and relapses
Prognosis and predictors of disease progression in multiple sclerosis
Professional Training:
1996 – 1999 PhD, Welsh School of Pharmacy, University of Wales, Cardiff, UK.
1991 – 1994 BPharm(Hons), School of Pharmacy and Pharmacology, Bath University, UK
Academic Positions:
October 2004 - Present
Assistant Professor, Faculty of Medicine (Neurology) and associate member of Health Care and Epidemiology, University of British Columbia, Canada. Funding: MS Society of Canada and The Michael Smith Foundation for Health Research (Scholar Award).
August 2001 - 2004
Post-doctoral Fellow, Faculty of Medicine (Neurology) University of British Columbia Funding: MS Society of Canada and The Michael Smith Foundation for Health Research.
Honours and Awards:
Multiple Sclerosis Society of Canada, Don Paty Career Development Award
Michael Smith Foundation for Health Research, Scholar Award
UBC Faculty of Medicine Merit and Performance Award
Jacqueline Du Pre Grant from the Multiple Sclerosis International Federation's (MSIF) Scientific Programmes Committee (International Medical & Scientific Board)
Publications
JOURNAL ARTICLES
Tremlett H, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551-554. [PubMed]
Tremlett H, Oger J. Adherence from across the pond: six-years of experience with the beta-interferons prescribed for Multiple Sclerosis. Pharmaceutical Journal 2003; 271:649-653.
Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im). Neurology 2004;62:628-631. [PubMed]
Tremlett H, Oger J. Elevated aminotransferases during treatment with Beta-Interferon for Multiple Sclerosis: actions and outcomes. Multiple Sclerosis 2004;10:298-30. [PubMed]
Tremlett H, Porciuncula J, Gibbs E, Oger J. Binding antibodies and aminotransferases in beta-interferon beta treated patients with multiple sclerosis. Journal of Applied Therapeutic Research 2004;5(1):12-16.
Tremlett HL,Oger J. Hepatic injury, liver monitoring and the beta-interferons for Multiple Sclerosis (Review). Journal of Neurology. 2004;251:1297-1303. [PubMed]
Tremlett HL, Porciuncula J, Oger J. Treatment with beta-interferon prior to glatiramer acetate diminishes the serum IgG response in multiple sclerosis patients. Journal of Applied Therapeutic Research 2004;5(2):12-16.
Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923. [PubMed]
Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology. 2006;66:172-177. [PubMed]
Tremlett H, Devonshire V. Does the season or month of birth influence disease progression in multiple sclerosis? Neuroepidemiology 2006;26:195-198. [PubMed]
Tremlett H, Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-959. [PubMed]
Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J. Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology 2006;67:1291-1293. [PubMed]
Sayao AL, Devonshire V, Tremlett H. Longitudinal Follow-up of Benign MS at 20 years. Neurology. 2007 Feb 13;68(7):496-500. [PubMed]
Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective Multiple Sclerosis. Mult Scler. 2008; 14:94-105. [PubMed]
Tremlett H, Zhao Y, Devonshire V. The natural history of secondary-progressive multiple sclerosis. Multiple Sclerosis. 2008. Apr;14(3):314-24. [PubMed]
Koch M, De Keyser J, Tremlett H. Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis 2008. Jul;14(6):793-8. [PubMed]
Tremlett HL, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 2008 Jun;17(6):565-76. [PubMed]
Forwell S, Brunham S, Tremlett H, Morrison W, Tentzerakis S, Bogle N, Oger J. Primary and non-primary fatigue in multiple sclerosis. International Journal of MS Care. 2008 In press
